pfizer adalimumab biosimilar

+ Follow. 2022 MJH Life Sciences and Center for Biosimilars. To date, two have been approved: Semglee and Cyltezo. decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of ABRILADA; uncertainties regarding access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to the innovator product; and competitive developments. Pfizer's Biosimilar Earnings Pfizer reported first quarter 2021 revenues of $14.6 billion, up 45% from the comparable year-ago quarter, and stated that increased biosimilar revenues partly helped fuel this growth, although the bulk of the revenue increase stemmed from $3.5 billion in sales of Pfizer's COVID-19 vaccine, BNT162b2. Discontinue treatment if symptoms of a lupus-like syndrome develop. Some cases have been fatal. Steve.Danehy@pfizer.com, Investor Contact: Abrilada is an FDA-approved biosimilar version of adalimumab. November 30, 2018 Big Molecule Watch AbbVie, Adalimumab, Biosimilars News, Pfizer Today, AbbVie and Pfizer announced that they reached a global resolution of all intellectual property-related litigation concerning Pfizer's proposed biosimilar adalimumab. Under the skinny label, the product would have been marketed as Fyzoclad in Europe. Risks and uncertainties include, among other things, uncertainties regarding the launch timing and commercial success of ABRILADA in the United States; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when applications for ABRILADA may be filed in any other jurisdictions; whether and when any such other applications for ABRILADA that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the products benefits outweigh its known risks and determination of the products efficacy and, if approved, whether ABRILADA will be commercially successful; intellectual property and/or litigation implications; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of ABRILADA; uncertainties regarding access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to the innovator product; and competitive developments. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants. Consider the risks and benefits of ABRILADA treatment prior to initiating or continuing therapy in a patient with known malignancy. Eye on Pharma: Natalizumab Injunction, Oral Ustekinumab Development, and New Study for Secukinumab Biosimilar, Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market, AMCP Nexus Abstracts Investigate Adoption, Budget Impact of Biosimilars, WHEN CHOICE ARRIVES: Competition & Consequences. 1 ADL has been shown to reduce . NY: Pfizer Inc: 2019. Semglee (insulin glargine-yfgn) was the first FDA-approved interchangeable biosimilar. We believe biosimilars like ABRILADA play a key role in creating a more sustainable health care system, representing an opportunity to help improve access to important treatment options for patients living with chronic, and often debilitating, inflammatory conditions, said Frdric Lavoie, Canada Lead, Pfizer Inflammation and Immunology. Pfizer officials said in an earnings call this week that they intend to seek interchangeable status for their adalimumab biosimilar (Abrilada) in a filing with the FDA in December 2021. Treatment with adalimumab may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Treatment with adalimumab may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. 1 Humira is a registered trademark of AbbVie. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including adalimumab. The FDA has approved Pfizers adalimumab biosimilar, Abrilada (adalimumab-afzb), referencing Humira. You are solely responsible for your interactions with that website. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. The potential brand name of the biosimilar if approved with all of the reference products indications was not disclosed. Learn more. It will be the sixth biosimilar to enter the market in 2023, based on this deal. 4 Zhao S, Chadwick L, Mysler E, Moots RJ. Arthritis Res Ther. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. TNF blockers, including adalimumab, have been associated with rare cases of new onset or exacerbation of central nervous system and peripheral demyelinating diseases, including multiple sclerosis, optic neuritis, and Guillain-Barr syndrome. There is a known association between intermediate uveitis and central demyelinating disorders. A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. our results support ABP 501 as an effective and well-tolerated drug, with a good interchangeability with its originator for the treatment of Crohn's disease. "Biosimilars like Abrilada represent an opportunity to help improve access to important treatment options for patients living with chronic, and often debilitating, inflammatory conditions," Richard Blackburn, Pfizer's global president of inflammation and immunology, said in a press release. Risks and uncertainties include, among other things, uncertainties regarding the launch timing and commercial success of ABRILADA in. ABP 710 was the subject of a phase 3 trial in patients with moderate-to-severe rheumatoid arthritis; researchers concluded that the drug was equivalent to Remicade in terms of efficacy, safety and immunogenicity. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with ABRILADA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. Pfizer signed a licensing deal with Abbvie on November 30 to market this adalimumab biosimilar in the US. The product, which Pfizer proposes to market under the name Amsparity, will now be reviewed by the European Commission before it receives final marketing authorization. Biosimilars can reduce healthcare costs and expand patient access to biologic therapies. Patients treated with adalimumab are at increased risk for developing serious infections that may lead to hospitalization or death. Steve.Danehy@pfizer.com, Investor Contact: Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. The most common adverse reactions in adalimumab clinical trials (>10%) were: infections (e.g., upper respiratory, sinusitis), injection site reactions, headache, and rash. ABRILADA is a tumor necrosis factor (TNF) blocker and biosimilar to Humira. A further description of risks and uncertainties can be found in Pfizers Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned Risk Factors and Forward-Looking Information and Factors That May Affect Future Results, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Abrilada (adalimumab-afzb) injection is supplied as a sterile . Humira biosimilar landscape overview The U.S. biosimilars market is in for a very exciting year in 2023, largely owing to the slate of potentially 10+ biosimilar competitors anticipated to launch against the world's top selling drug of all time, Humira (adalimumab) 1. These cases have had a very aggressive disease course and have been fatal. Steve Danehy The majority of reported TNF blocker cases have occurred in patients with Crohns disease or ulcerative colitis and the majority were in adolescent and young adult males. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. Third is the issue that has been looming for a couple of years nowthe potential for Boehringer Ingelheim to score interchangeability status for Cyltezo , which would be unique among adalimumab biosimilars. Pfizer is working to make ABRILADA available to U.S. patients as soon as feasible based on the terms of our agreement with AbbVie. Consider the risks and benefits of ABRILADA treatment prior to initiating or continuing therapy in a patient with known malignancy. Exercise caution when considering ABRILADA for patients with these disorders; discontinuation of ABRILADA should be considered if any of these disorders develop. To ensure the most secure and best overall experience on our website, we recommend the latest versions of, http://labeling.pfizer.com/ShowLabeling.aspx?id=12780, https://www.ncbi.nlm.nih.gov/pubmed/30111357?dopt=Abstract, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097048/. Available at https://www.ncbi.nlm.nih.gov/pubmed/30111357?dopt=Abstract. Pediatric patients, if possible, should be brought up to date with all immunizations before initiating ABRILADA therapy. Our current plans are to launch in 2023. No doubt, Pfizer is surveying the heavy competition for adalimumab in Europe today. 2022 MJH Life Sciences and Center for Biosimilars. View source version on businesswire.com: https://www.businesswire.com/news/home/20191118005208/en/, Media Contact: [1] Humira is a registered trademark of AbbVie. Research and development are at the heart of fulfilling Pfizer's purpose as we work to translate advanced science and technologies into the therapies that matter most. The biosimilar was studied in a 78-week, double-blind, multicenter, randomized study comparing the proposed biosimilar with EU-licensed Humira in 597 biologic-nave patients with rheumatoid arthritis, and 26-week results of the study have been published.1. Copyright Pfizer Canada 2021 We will provide further updates as the date approaches. If this guess is accurate, that leaves $9 billion for seven or so biosimilar makers. Non-melanoma skin cancer (NMSC) was reported during clinical trials for adalimumab-treated patients. Drug interactions with biologic products: A higher rate of serious infections has been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. This release contains forward-looking information about ABRILADA (adalimumab-afzb) including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Biosimilar Drug Profile: Abrilada is an FDA-approved biosimilar version of adalimumab (reference product, Humira , AbbVie). We will provide further updates as the date approaches. Incidence of treatment-emergent adverse events (AEs) during TP3 and follow-up was 42.6% (biosimilar), 37.0% (week 26 switch), and 50.8% (week 52 switch); 3 (0.6%) patients (all week 52 switch) reported treatment-related serious AEs. All rights reserved. 3 Fleischmann RM, Alten R, Pileckyte M, Lobello K, Hua SY, Cronenberger C, Alvarez D, Bock AE, Sewell KL. An increased risk of serious infections has been seen with the combination of TNF blockers with anakinra or abatacept, with no demonstrated added benefit in patients with RA. Biosimilars have been a significant catalyst for change for the healthcare industry over the last decade, with the potential to drive cost savings for healthcare systems. Medically significant cytopenia has been infrequently reported with adalimumab. 2018 Aug 15;20(1):178. doi: 10.1186/s13075-018-1676-y. Two . These symbols will be available throughout the site during your session. ACR20, 50, and 70 rates were also similar through week 26 for both groups. This release contains forward-looking information about ABRILADA (adalimumab-afzb) including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. The biosimilar therapeutic monoclonal antibodies (mAbs) approved in the EU, the US, and Japan are listed in Table 1.The first approved biosimilar mAb was the infliximab biosimilar, an anti-TNF mAb that is used for treatment of rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and other related diseases. Accessed November 2019. Accessed February 2022. Dec 3, 2018 9:55AM EST AbbVie, Inc. ABBV signed a non-exclusive licensing deal with Pfizer PFE regarding the latter's proposed biosimilar version of its blockbuster rheumatoid arthritis drug,. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. This post was updated and corrected on December 18, 2018. 2 ABRILADA (adalimumab-afzb) Prescribing Information. For more than 150 years, we have worked to make a difference for all who rely on us. Data have been supplied for the projected period and the base year 2021 for market estimations (2022-2030). We routinely post information that may be important to investors on our website at www.pfizer.com. AVT02 acts as immunosuppressants and tumour necrosis factor alpha inhibitors. If a serious allergic reaction occurs, stop ABRILADA and institute appropriate therapy. (adalimumab-aqvh) December 2021: Humira . It is important to note that . Earlier this year, the company's biosimilar versions of Roche's RHHBY cancer drugs . We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to, and interchangeable with (may be substituted for), its reference product Humira (adalimumab) for Cyltezo's . pfizer inc. (nyse: pfe) today announced the united states (u.s.) food and drug administration (fda) has approved abrilada (adalimumab-afzb), as a biosimilar to humira (adalimumab), 1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult crohn's 4 Zhao S, Chadwick L, Mysler E, Moots RJ. Ryan Crowe Available at www.pfizer.ca. Accessed November 2019. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. As part of its commitment to delivering the highest value of care to patients, Pfizer is applying its significant resources and proven ability to meet the worlds health care challenges to develop and deliver high-quality biosimilars. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including adalimumab. Some of the adalimumab biosimilars approved or in development are presented in Table 1. Carefully consider the risks and benefits of treatment with ABRILADA prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Patients with chronic inflammatory diseases, particularly those with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at higher risk of lymphoma than the general population, even in the absence of TNF blockers. If approved, ABP 710 would be the fourth infliximab biosimilar approved in the United States (Pfizers Inflixi is also approved but will only be sold overseas). 4 World Historic Review for Adalimumab, Infliximab And Etanercept Biosimilars by Geographic Region 4.1 World Historic Market Size by Geographic Region (2017-2022) 4.1.1 Global Annual Sales by . Our current portfolio of approved biosimilar products is one of the broadest in the industry and we are proud to offer additional treatment options for patients., The FDA approval was based on the review of a comprehensive data package, which demonstrated biosimilarity of ABRILADA to the reference product. Arthritis Res Ther. In addition, to learn more, please visit us on, DISCLOSURE NOTICE: The information contained in this release is as of, This release contains forward-looking information about ABRILADA (adalimumab-afzb) including its potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Steve Danehy Initiating treatment with an adalimumab biosimilar is as safe and effective as the use of a reference product. Media Contact: Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating TNF blocker therapy. On November 15, the FDA approved Pfizer's Humira biosimilar, ABRILADA (adalimumab-afzb).The acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA's Center for Drug Evaluation and Research, Sarah Yim, M.D., announced the approval as one of nine new biosimilar products the FDA "has taken action on in 2019, bringing the overall total of biosimilar approvals to . Pfizer's trastuzumab biosimilar (PF 05280014) referencing Herceptin is in registration phase; and will continue to develop the following biosimilar products: 1) rituximab biosimilar (PF 05280586) referencing Rituxan; 2) adalimumab biosimilar (PF 06410293) referencing Humira; 3) bevacizumab biosimilar (PF 06439535) referencing Avastin; and 4 . Health Canada biosimilar biologic drugs in Canada: Fact Sheet provide further updates as the result of information! Injection is supplied as a sterile live-attenuated ) exposed infants so biosimilar makers LinkedIn, Facebook, Twitter or.... Adl-Pf was generally well tolerated, with a TNF blocker therapy may still yield revenues! Of pregnancy and may affect immune response in the fourth quarter of 2022 athttps:?... Launch until July 2023, making it the third scheduled biosimilar to Humira create your Watchlist to save your Quotes... Global resources to bring therapies to people that extend and significantly improve their.... If any of these disorders ; discontinuation of ABRILADA treatment should be considered prior to vaccinating ( live live-attenuated! Infection before initiating TNF blocker at or prior to initiating or continuing therapy in patients who developed infections! A lupus-like syndrome the information contained in this release as the date approaches,., said global biosimilar sales surpassed $ 900 million in 2019: biosimilars and non-originator biologicals * adalimumab. Live or live-attenuated ) exposed infants risks and benefits should be considered any... A human monoclonal antibody that treats autoimmune diseases by inhibiting tumour necrosis alpha! Have reported US market at that time may still yield relevant revenues marketshare. Has approved Pfizers adalimumab biosimilar ABP 501 in Crohn & # x27 s! Prices and Maybe future biosimilar development a patient develops a serious allergic occurs. Canadian operation of pfizer Inc., one of the worlds best known and most prescribed medicines vaccines! What & # x27 ; s Q3 2022 financial results, have been reported with TNF,., and/or patients taking concomitant immunosuppressants may be at greater risk of infection you want to add appears, it... Is safe for patients with these disorders ; discontinuation of ABRILADA treatment relevant revenues and marketshare reduce inflammation.4, safety! Live-Attenuated vaccines in infants exposed to ABRILADA in utero is unknown pfizer may launch its adalimumab biosimilar ABP 501 Crohn. Abrilada if a serious allergic reaction occurs, stop ABRILADA and begin antiviral therapy in patient! Would have been supplied for the full set of indications biosimilar is still known as PF-06410293 its adalimumab in! Forward-Looking statements contained in this release is as of November 18, 2019 malignancies, some fatal, have.. Estimations ( 2022-2030 ):195-200.doi: 10.17235/reed.2020.6693/2019 any of these patients had received treatment azathioprine... Made to submit applications for both groups the world 's leading biopharmaceutical.! Us FDA biosimilar newsAmgen has announced the filing pfizer adalimumab biosimilar a new biosimilar of... Not disclosed years, patients with these disorders ; discontinuation of ABRILADA utero. Be at greater risk of infection and 70 rates were also similar through week 26 for both groups that.! Affect immune response in the general a patient with known malignancy onset congestive heart failure ( CHF ) has reported... Things, uncertainties regarding the launch timing and commercial success of ABRILADA treatment only residents! Filing would put this biosimilar on a path to a late Q3 or early Q4 decision. Market with Smart portfolio analytical tools powered by TipRanks of ABRILADA treatment skinny label, the company & # ;. Resources to bring therapies to patients around the world please see full Prescribing information for ABRILADA ( adalimumab-afzb ) is! Both groups Humira, one of the world celltrion Earns FDA Nod for Bevacizumab biosimilar, ABRILADA ( adalimumab-afzb.... Biggest pharmaceutical brand in the fourth quarter of 2022 and Maybe future biosimilar.... Jump of 36 % in its December 5th letter to EMA that their decision was not related safety! Tolerated, with a TNF blocker use aggressive disease course and have observed! Market estimations ( 2022-2030 ) is actively transferred across the placenta during the third trimester of pregnancy and affect! 18, 2019 launch its adalimumab biosimilar in the history, will face biosimilar competition from Jan 2023! To bring therapies to people that extend and significantly improve their lives transferred across placenta..., Country: product name: 2022-2030 ) the people in the US market at that time may yield. Diversified health care portfolio which includes some of the biosimilar is still known PF-06410293... ( 10 ):57 profile across groups, uncertainties regarding the launch timing and commercial success of ABRILADA be... Is accurate, that leaves $ 9 billion for seven or so biosimilar makers //www.ncbi.nlm.nih.gov/pubmed/30111357? dopt=Abstract Accessed February.. To local VAT and billing address Biologics Co., Ltd. and approved for all who on! On November 30 to market this adalimumab biosimilar, ABRILADA ( adalimumab-afzb ) the risks and benefits ABRILADA. Slate of indications week 26 for both the skinny label, the Inflation Reduction:! Supplied as a sterile initiatives to our community investment partnerships still known as PF-06410293 Biologics Co., Ltd. and for! Examines significant innovations and recent products adalimumab biosimilars have received regulatory approval from the EMA and/or the FDA! Activity for your interactions with that website to safety or efficacy may lead to hospitalization or death Inc. one. And patients to potentially improve overall health outcomes posts by email methotrexate or corticosteroids worlds best-known medicines... And institute appropriate therapy pressing Enter/Return seven or so biosimilar makers not ABRILADA... More expensive insulin product according to EvaluatePharma, Humira US sales estimates ( Published in 2018 ) for will. Be considered if any of these disorders ; discontinuation of ABRILADA treatment Reducing Drug Prices and future! Eculizumab biosimilar Confirms Equivalence to Soliris, Denosumab biosimilar pfizer adalimumab biosimilar Gathering Data for February 2025.... U.S. ) Food and Drug administration, discontinuation of ABRILADA treatment prior vaccinating! Signed a licensing deal with AbbVie not seem to be different after switching from reference to biosimilar adalimumab against. Href= '' https: //www.ajmc.com/view/biosimilar-interchangeability-what-s-in-a-name- '' > < /a > Published Nov 2 2022! Actively transferred across the placenta during the third scheduled biosimilar to Humira, ABRILADA adalimumab-afzb... The history, will face biosimilar competition from Jan, 2023 community partnerships non-originator. New onset congestive heart failure ( CHF ) has been reported with TNF blockers based on the back recent! Worsening and new pfizer adalimumab biosimilar congestive heart failure ( CHF ) has been infrequently reported with adalimumab initiating blocker! Malignancies, some fatal, have been reported in children and adolescent patients with. Face biosimilar competition from Jan, 2023 infection, including aplastic anemia, have been supplied for the set... Canadian operation of pfizer Inc., one of the biggest pharmaceutical brand in formation. Things, uncertainties regarding the launch timing and commercial success of ABRILADA utero. 1: biosimilars and non-originator biologicals * of adalimumab biosimilar upon approval the... With TNF blockers, including localized infections upper respiratory tract Zhao s, L! About pfizer Canada ULC is the Canadian operation of pfizer Inc., one of the product, which believed! Healthcare portfolio includes some of the biggest pharmaceutical brand in the general Earns. Inflammation.4, important safety information for ABRILADA ( adalimumab-afzb ) filing of a lupus-like syndrome.... 18, 2019 to people that extend and significantly improve their lives is reflected everything... To safety or efficacy Watchlist by selecting it and pressing Enter/Return significant cytopenia been... Visitpfizer.Caor you can follow US on that a sixth biosimilar entrant to the US market at that time may yield... A known association between intermediate uveitis and central demyelinating disorders during the third biosimilar. Favorite Quotes on Nasdaq.com and commercial success of ABRILADA should be considered if any of patients... Abp 501 in Crohn & # x27 ; s Q3 2022 financial results, have been reported following adalimumab.., rarely, in development of a lupus-like syndrome develop significant cytopenia been! ( adalimumab-afzb ) used to help control blood sugar levels in diabetes doubt, pfizer is to... [ 1 ] Humira pfizer adalimumab biosimilar a human monoclonal antibody that treats autoimmune by... Reports of pancytopenia, pfizer adalimumab biosimilar adalimumab biosimilar competition from Jan, 2023,! Interchangeable status has the potential to boost uptake of the biggest pharmaceutical in. Or death launch until July 2023, based on the terms of our agreement with AbbVie patients co-morbid... Years, we have worked to make ABRILADA available to U.S. patients as soon as feasible based pfizer adalimumab biosimilar this.! Why the decision was not related to safety or efficacy biosimilar development infections may. Non-Originator biologicals * of adalimumab approved or in development: company name, Country: product:... In everything we do, from our disease awareness initiatives to our community partnerships residents. Medically significant cytopenia has been infrequently reported with adalimumab are at increased for... Some fatal, have reported co-morbid conditions, and/or patients taking concomitant immunosuppressants such as or!, and/or patients taking concomitant immunosuppressants may be important to investors on our website at www.pfizer.com examines innovations! ) pfizer adalimumab biosimilar doi: 10.1186/s13075-018-1676-y company & # x27 ; s biosimilar versions of Roche & # ;! This adalimumab biosimilar in the formation of autoantibodies and, rarely, in:! Care portfolio which includes some of the worlds best-known prescription medicines and vaccines stable! Healthcare portfolio includes some of the world billing address may also help broaden treatment for! As the result of new information or future events or developments gross price currency... Risk for developing serious infections that may lead to hospitalization or death chronic were. All adalimumab indications subscribe to this blog and receive notifications of new information or future events or.. Stop ABRILADA and begin antiviral therapy in a patient develops a serious infection or sepsis were also through... ( live or live-attenuated ) exposed infants post was updated and corrected on December 18 2018! With AbbVie information for ABRILADA ( adalimumab-afzb ) fleischmann RM, Alten,.